Abstract. Heart failure is a major cause of death in developed countries, and the development of an epoch-making cure is desired from the viewpoint for improving the quality of life and reducing the medical cost of the patient. The importance of neurohumoral factors, such as angiotensin (Ang) II and catecholamine, for the progression of heart failure has been supported by a variety of evidence. These agonists stimulate seven transmembrane-spanning receptors that are coupled to heterotrimeric GTP-binding proteins (G proteins). Using specific pharmacological tools to assess the involvement of G protein signaling pathways, we have revealed that α subunit of G q (Gα q ) activates Ca 2+ -dependent hypertrophic signaling through diacylglycerol-activated transient receptor potential canonical (TRPC) channels (TRPC3 and TRPC6: TRPC3/6). In contrast, activation of Gα 12 family proteins in cardiomyocytes confers pressure overload-induced cardiac fibrosis via stimulation of purinergic P2Y 6 receptors induced by extracellular nucleotides released from cardiomyocytes. In fact, direct or indirect inhibition of TRPC3/6 or P2Y 6 receptors attenuates pressure overload-induced cardiac dysfunction. These findings will provide a new insight into the molecular mechanisms underlying pathogenesis of heart failure.
Introduction
Heart failure is a final stage of every cardiovascular disease, including chronic hypertension, aortic stenosis, and myocardial infarction. In an early stage of heart failure, the heart changes its structure and morphology (remodeling) to adapt itself from hemodynamic overload. However, progression of cardiac remodeling, including cardiomyocyte hypertrophy and collagen deposition (fibrosis), adversely promotes myocardial stiffness and left ventricular dilation, resulting in progression of heart failure (1). Thus, preventing the progression of cardiac remodeling is expected to suppress the progression of heart failure. As hyperfunctions of sympathetic nerve system and renin-Ang II-aldosterone system have been implicated in the progression of heart failure, hormonal disorder is thought to be a primary cause of heart failure.
G protein-coupled receptors (GPCRs) are a conserved family of seven transmembrane spanning receptors that occupy the majority of receptors in the genome, and about 40% of the drugs used for therapeutic treatment all over the world may directly or indirectly target GPCRs (2) . Although it has been estimated that 200 kinds of GPCRs are expressed in the myocardium, most of the therapeutic drugs for the heart failure target only 2 receptors, β 1 adrenergic receptor (β 1 AR) and angiotensin (Ang) II type 1 receptor (AT 1 R). However, the blockers against β 1 AR and AT 1 R are not necessarily sufficient for the treatment of heart failure patients. Thus, researchers have explored the underlying molecular mechanisms of heart failure in the hopes of identifying novel therapeutic tar-gets, including GPCR(s) and the components that participate in GPCR signaling pathways in failing hearts (3).
Pharmacological assessment of G protein signaling pathways
G proteins form a heterotrimer comprised of α, β, and γ subunits at the resting state. The activated form of the receptor can catalyze the exchange of GTP for GDP bound to the α subunit (Gα) of specific G protein, leading to dissociation of Gα from the βγ dimer (Gβγ). Both Gα and Gβγ couple with the respective effectors to activate the independent signaling pathways. The Gα has an intrinsic GTPase activity to hydrolyze GTP into GDP, and GTP hydrolysis will terminate the activation of G protein signaling. The conformation switch between the GDP-bound state and GTP-bound state is called the "G (protein) cycle" (Fig. 1) .
G proteins are classified into four families (G s , G i , G q , G 12 ) on the basis of amino acid sequence similarity and the functional difference of an effector molecule activated by Gα. Activation of each G protein signaling can be evaluated by the production of second messenger through activation of its effector enzyme. Commercial toxins or reagents that activate or inactivate the specific G protein signaling have become able to evaluate easily the involvement of G protein in various cellular functions. However, attention will be required for the interpretation of the results obtained using these toxins. In fact, we found that Pertussis toxin (PTX), which ADPribosylates Gα i and uncouple receptors from G i , stimulates toll-like receptor 4 that leads to an increase in the number of AT 1 Rs (4). In order to overcome these problems, biological approaches to inhibit the function of a specific G protein have been conducted. For example, overexpression of each carboxyl-terminal region of Gα (Gα-ct) can induce subtype-specific inhibition of G protein signaling by the competition of corresponding Gα to couple with receptors (5, 6) . In addition to Gα-ct, there is another tool to specifically inhibit Gα-mediated signaling. Regulator of G protein signaling (RGS) proteins function as GTPase-activating protein (GAP) of G proteins, which promotes the inactivation of G proteins. Thus, an RGS domain polypeptide specifically inhibits one or more Gα-mediated signaling pathways. There are four tools to inhibit Gβγ-mediated signaling. Among them, a carboxyl-terminal region of β-adrenergic receptor kinase 1 [βARK-ct, βARK is also called G proteincoupled receptor kinase 2 (GRK2)] specifically inhibits Gβγ-mediated signaling (7) . In addition, activator of G protein signaling (AGS) 8 is reported to promote a Gβγ-dependent signal (8) , and nucleoside diphosphate kinase (NDPK), which induces phosphorylation of the His 266 residue of Gβ to form a signal complex with Gβγ, promotes Gα s -mediated cAMP production without receptor stimulation, resulting in enhancement of cardiac muscle contractility (9) . Thus, AGS8 and NDPK can also be a tool to activate G protein signaling pathways by inhibiting heterotrimer formation of Gα with Gβγ.
Roles of G proteins in the progression of heart failure
Results of the studies using transgenic and KO mice have revealed that G s protein participates in positive inotropic and chronotropic effects induced by βAR stimulation and G i/o proteins participate in a negative chronotropic effect induced by muscarinic M 2 receptor stimulation (10) . On the other hand, neurohumoral factors, such as Ang II, endothelin (ET)-1, and catecholamine, induce structural changes of the heart and cardiac dysfunction through activation of G q and G 12 family protein signaling pathways. Here, I will introduce recent our findings about the pathophysiological role of each G protein family in heart failure. (13) . The I-V relationship of Ang II-induced currents supported the evidence that the currents are TRPC-like. TRPC channels have been originally proposed as store-operated channels activated by Ca 2+ depletion of stores, while closely related TRPC3, TRPC6, and TRPC7 showed activation sensitivity to the membrane-delimited action of diacylglycerol (DAG). We have found that TRPC3 and TRPC6, but not TRPC7, participate in agonist-and mechanical stretch-induced cardiomyocyte hypertrophy in vitro (14) . In fact, chronic treatment with a novel TRPC3-selective inhibitor after surgical transverse aortic constriction suppressed pressure overload-induced cardiac hypertrophy in vivo (15) . Thus, TRPC3/6 proteins may assemble to form DAGactivated cation channels, which mediate the Gα q -induced cardiac hypertrophy (Fig. 2) . Although physiological roles of TRPC3/6 channels are still unknown, these results suggest that DAG-activated TRPC channels are a potential therapeutic target for the treatment of heart failure.
Purinergic P2Y 6 R-Gα 12/13 signaling triggers pressure overload-induced cardiac fibrosis
As G 12/13 proteins do not participate in the production of second messengers, such as cAMP and Ca 2+ that can be detected with high sensitivity, and a specific inhibitor of G 12/13 signaling including a toxin has not been found, roles of G 12 family proteins (G 12 and G 13 : G 12/13 ) have hardly been analyzed (10) . Both activated Gα 12 and Gα 13 can combine with GDP/GTP exchange factor of small G protein Rho (RhoGEF), which leads to increase in Rho activity. Thus, Rho activity is thought to be the best index for evaluating the magnitude of activation of Gα 12/13 signaling. Using the adenoviral gene transfer method to express Gα 12/13 -specifc inhibitory polypeptide (RGS domain of p115 RhoGEF: p115-RGS), we found that G 12/13 proteins could be activated by the stimulation of AT 1 R, ET-1 type A receptor, or α 1 -adrenergic receptor in rat cardiomyocytes (5, 6, 16) . These are G q protein-coupled receptors responsible for cardiomyocyte hypertrophy, and the hypertrophic growth of cardiomyocytes induced by receptor stimulation are suppressed by p115-RGS. Activation of Gα 12/13 by AT 1 R stimulation induces activation of small G protein Rac through activation of Rho and Rho-associated coiled-coil-containing protein kinase (ROCK). In addition, Rac mediates Ang II-induced generation of reactive oxygen species (ROS) through NADPH oxidase, and generated ROS subsequently activate stress-activated protein kinase [(SAPK: c-Jun NH 2 -terminal kinase (JNK) and p38MAPK)] (16). As NADPH oxidase is the only enzyme found in the downstream of the Gα 12/13 proteins and the other three G proteins (G s , G i , G q ) activate intracellular signaling pathways and produce respective second messengers, ROS may work as a second messenger of the G 12/13 protein signaling.
In contrast, pressure overload-induced cardiac hypertrophy was not suppressed in transgenic mice with cardiomyocyte-specific overexpression of p115-RGS (p115-RGS-Tg). This result suggests that the molecular mechanism underlying in vitro hypertrophy induced by GPCR stimulation is different from that underlying pressure overload-induced cardiac hypertrophy in vivo. However, interstitial fibrosis and left ventricular diastolic functions were significantly attenuated by the inhibition of myocardial Gα 12/13 signaling (17) . In addition, transgenic mice with cardiomyocyte-specific overexpression of a constitutively active mutant of Gα 13 (CA-Gα 13 ) have been shown to have interstitial fibrosis without accompanying cardiomyocyte hypertrophy. The pressure overload-induced activation of Rho, Rac, SAPK, and increase in the expression levels of fibrogenic factors, including transforming growth factor (TGF)-β, periostin, and connective tissue growth factor (CTGF), were remarkably suppressed in p115-RGS-Tg mice. Furthermore, we revealed that extracellular nucleotides released from cardiomyocytes through pannexin-1 hemi-channel induced by mechanical stretch induces stimulation of purinergic P2Y 6 receptor-Gα 12/13 signaling in cardiomyocytes, initiating pressure overload-induced cardiac fibrosis. Although cardiac fibrosis is believed to be accompanied with Gα q -mediated pathological hypertrophy that eventually results in heart failure, our results clearly show that cardiac fibrosis and hypertrophy are independent processes. As pannexin-1 and P2Y 6 R mRNAs in the heart are up-regulated by pressure overload, Gα 12/13 -mediated signaling leading to cardiac fibrosis may turn on after myocardial hypertrophy.
Cross-talk between Ang II signaling and purinergic signaling
Extracellular ATP in the cardiovascular system may be originated from various cellular sources: perivascular sympathetic nerve endings, myocytes, endothelial cells, and inflammatory cells. We revealed that nucleotides released from cardiac myocytes activate P2Y 6 R of cardiac myocytes and induce fibrotic genes. In addition, stimulation of P2Y 2 R by UTP induces fibrotic responses of cardiac fibroblasts (18) . Thus, extracellular nucleotides contribute to cardiac fibrosis at least two independent pathways: one is induction of fibrotic genes in cardiac myocytes through P2Y 6 R and another is iNOS-mediated Fig. 3 . Postulated function of purinergic receptor-mediated NO signaling in the progression of cardiac remodeling. In the early stage of pressure-overloaded hearts, circulatory and systemic renin-Ang systems are activated due to decrease in renal blood flow and mechanical stress of the cardiovascular system. Continuous activation of Ang II signaling may in turn stimulate purinergic signaling via increases in nucleotide release from nerve endings and densities of P2Y2R and P2Y6R (17) , leading to heterologous down-regulation of AT1R signaling (19) . Purinergic signaling may initially work as a negative regulator of Ang II signaling, but it also induces chronic inflammation through iNOS-mediated signaling pathways. signaling in cardiac fibroblasts through P2Y 2 R (19). Although both ATP and Ang II work as an inflammatory factor, their functions in the heart seem to be different. For example, treatment with ATP markedly increases NFAT activity, but does not induce cardiomyocyte hypertrophy (20) . Most recently, we have revealed that stimulation of P2Y 2 R by ATP decreases AT 1 R density through expression of inducible nitric oxide (NO) synthase (iNOS) (19) . The iNOS-mediated NO induces covalent modification of cysteine thiol (S-nitrosylation) in nuclear factor κB (NF-κB), leading to suppression of AT 1 R transcriptional activity. Thus, purinergic signaling may negatively regulate Ang II signaling through iNOS production in an early stage of heart failure, but accordingly induce chronic inflammation through activation of NO-based signaling (Fig. 3) .
Conclusion
Cardiac fibrosis has been believed to be accompanied with Gα q -mediated pathological hypertrophy that eventually results in heart failure. However, our results clearly show that cardiac fibrosis and hypertrophy are independent processes. Constructing pharmacological tools for analyzing G protein signaling pathways, we identified new therapeutic targets (TRPC3/6 channels, P2Y 6 receptor) for the treatment of heart failure. Further studies using cardiomyocyte-specific conditional knockout mice will establish the importance of these proteins in heart failure. In the future, a better understanding of the components that participate in GPCR signaling pathways in healthy and failing hearts may provide a mechanistic basis for improving heart failure treatment.
